CS Paper Radar

Multi-Objective Amortized CDRH3 Sequence Sampling Diversifies Promising Antibody Candidates

Joseph D. Viviano, Almer van der Sloot, Quentin Fournier, Robert M. Vernon, Christopher James Langmead, Yoshua Bengio

cs.CE ·submitted 2026-10-12 15:05 UTC · v1

Abstract

Antibody therapeutics have transformed treatment across diverse therapeutic areas and have become central to modern medicine. While recent machine learning approaches aim to accelerate antibody discovery through structure-based design and target-affinity optimization, successful candidates must also satisfy broad developability constraints, including structural compatibility, low immunogenicity, and favorable biophysical properties, while remaining sufficiently diverse to provide sufficient coverage of design space to mitigate later-stage development failures. We introduce a preference-conditioned multi-objective generative flow network (GFN) fine-tuning pipeline for fixed-framework CDRH3 loop redesign that fine-tunes a biological sequence model against many inexpensive proxies covering backbone compatibility, sequence likelihood, immunogenicity risk, novelty, and developability liabilities. It combines up to fourteen predictive rewards in a single policy trained to sample CDRH3 loops across 623 SAbDab antibody structures, leveraging a reward reduction strategy to preserve Pareto dominance under this learned map. We also introduce a novel autoregressive span-in-filling variant of AMPLIFY-350M that serves both as a scaffold-conditioned CDRH3 generation prior and as a direct conditional likelihood scorer. We evaluated reward scores, diversity, and design quality on loops sampled on 45 held-out antibody complexes to assess structural consistency, confidence, aggregation propensity, stability, and antigen binding. Compared with the inverse-folding methods ProteinMPNN and ESM-IF, our approach produces roughly 10x more distinct acceptable candidates per design at 50% sequence identity, while holding 10% of the 14-objective Pareto front pooled across methods, trading per-sample quality for greater exploration of novel possible structures.

Comment
21 Figures, 14 Tables, Under review

Closest papers

Nearest neighbours by meaning across the whole index.

iGC: Antibody Optimization via Reinforcement Learning over a Learned Somatic Hypermutation Prior

cs.LG q-bio.BM ·2026-11-03 ·Thao Nguyen, Robert G. Alberstein, Ewa Nowara, Homa MohammadiPeyhani, Holly R. Steach +8 more
similarity 0.68
Abstract · 10 pages with supplementary documents

Antibody affinity maturation is a natural optimization process in which B cells acquire mutations through somatic hypermutation (SHM), undergo selection for improved antigen binding, and iteratively evolve toward higher affinity. Computationally modeling this process requires capturing both biologically plausible mutations and antigen-specific selection. However, existing mutation models do not directly optimize binding, while affinity optimization often neglects realistic mutation trajectories. We introduce iGC (in silico Germinal Centers), a two-stage reinforcement learning (RL) framework for antigen-specific antibody optimization. Stage 1 learns an SHM mutation prior from parent-child pairs in B-cell lineage trees and adapts it to a target affinity-maturation dataset. Stage 2 initializes an RL policy from this prior and optimizes antigen binding with Kullback-Leibler (KL) regularization toward the frozen prior. To prevent reward exploitation, including repetitive high-reward substitutions and structurally tolerated framework mutations, we introduce a Reward-Tax Meta-Gradient objective. RewardNet smooths the affinity landscape, while TaxNet penalizes reward overexploitation, jointly defining a learned meta-reward for policy optimization. We evaluate iGC on mutation prediction, SHM consistency, affinity optimization, and mutation diversity. The mutation prior more than doubles the strongest baseline in mutation-site prediction. Following RL optimization, iGC maintains SHM sequence structure. It also achieves a strong exploration-exploitation balance, yielding competitive reward-diversity products across candidate-selection cutoffs. These results demonstrate that iGC integrates biologically plausible mutation generation with antigen-specific affinity selection, providing an in silico framework for iterative antibody affinity maturation.

0.19

Probabilistic Steering of Generative Priors for Lab-in-the-Loop Antibody Optimization

cs.LG ·2026-11-02 ·Anisha Parsan, Sebastian Ober, Calvin McCarter, Nick Bhattacharya, Hunter Elliott
top venue similarity 0.68
Abstract · Accepted to NeurIPS `26 GEM and NeurIPS `26 AI4DD

Therapeutic antibody development is often framed as comprising two discrete stages: initial discovery of novel binders followed by iterative optimization to refine these hits into therapeutic-grade molecules. Models and methods often reflect these stages, with generative structure models applied to discovery and probabilistic black-box optimization methods applied to refinement. Here we propose to unify these stages by smoothly transitioning a generative discovery model into iterative optimization, allowing the handoff between the structure-based prior and supervision from wet lab data to be guided by the posterior uncertainty of a probabilistic surrogate. We show that this yields improvements in optimization efficiency in the low-N regime, as well as improved diversity amongst the optimized molecules.

0.36

Multi-Objective Protein Optimization via Modular Diffusion Steering

cs.LG ·2026-10-20 ·Meir Roketlishvili, Felix Huber, Wenda Chu, Yisong Yue, Raul Astudillo
similarity 0.64
Abstract

Protein engineering often requires improving several properties simultaneously, motivating the search for high-performing sequences that represent useful fitness tradeoffs. Discovering these sequences is challenging because the design space is combinatorially large and experimental campaigns often permit only a few rounds of batched measurements. We introduce \textit{MODS}, a modular framework for multi-objective protein optimization via inference-time diffusion steering. For each proposal, MODS samples augmented Chebyshev scalarization weights and a fitness-surrogate ensemble member to define a scalar steering reward. Varying the weights directs generation toward different objective tradeoffs, while varying ensemble members diversifies the predictions used for guidance. Because MODS expresses multi-objective acquisition through scalar rewards, it can be paired with different diffusion models and compatible steering procedures. After each evaluation batch, MODS updates the surrogates without retraining the generative model. We evaluate MODS on six protein optimization tasks using predictive oracles trained on experimental assay data, with two diffusion models and two steering procedures. MODS achieves competitive final hypervolume across all six tasks with both diffusion models, and substantially outperforms the best evaluated baseline on several tasks. Our results demonstrate a flexible and effective approach to multi-objective protein optimization with limited feedback.

0.08

Multimodal reasoning for broadly neutralizing antibody discovery from label-free human B cell repertoires across virus families

cs.AI q-bio.QMcs.CEq-bio.CB ·2026-10-02 ·Hantao Lou, Jianqing Zheng, Can Yue, Meihan Zhang, Yuanchao Bao +19 more
similarity 0.62
Abstract

Discovering broadly neutralizing antibodies (bnAbs) from human natural immune repertoires remains a fundamental challenge in immunology, hindered by: the extreme rarity of bnAb, incomplete understanding of their cellular origins across pathogens, and the inability of existing computational tools to generalize across emerging viral threats. Here we present ImmuneAgent, a closed-loop AI system that integrates multimodal reasoning with continual meta-learning and wet-lab feedback to overcome these barriers. Applied to screen the natural BCR repertoires from vaccinated or infected cohorts, the system achieves a ~55% neutralization antibody discovery rate (60 of 110 cloned candidates) and a ~11% bnAb yield (12 of 110), substantially outperforming a state-of-the-art sequence-based neutralization predictor or cofolding models evaluated at the same cloning budget. Five ImmuneAgent-discovered antibodies conferred 100% in vivo protection against lethal influenza challenge, comparable to the clinical-stage therapeutic MEDI8852. The system recovered the cellular and structural determinants of bnAb activity and identified FCRL5+CD27+ atypical memory B cells as a conserved bnAb reservoir and hydrophobic interface enrichment as a cross-viral structural signature, which generalized to unseen antigens, discovering human metapneumovirus (hMPV) cross-neutralizing and human papillomavirus (HPV)-neutralizing antibodies without antigen-specific sorting. These results validate that ImmuneAgent is a generalizable framework for rapid therapeutic antibody discovery against emerging viral threats.

0.20

ProteoCraft: Protein Design as Proposal-Verification Search

cs.CE cs.AIq-bio.BM ·2026-11-02 ·Fang Wu, Hongbin Lin, Bingchen Duan, Yuchen Wang, Li Erran Li +22 more
code/data similarity 0.62
Abstract

Protein-protein interactions underpin nearly all biological processes. Yet, designing proteins with desired interactions remains challenging due to the structural complexity governing molecular recognition. This study views protein design as a search optimization problem over a combinatorial sequence space under expensive structural evaluation. Toward this goal, we introduce a novel tree-based search framework, ProteoCraft, that employs approximate structural gradients from diffusion-based structure predictors as effective proposal policies to specify where the search should explore. Complete no-gradient inference of folding models separately assigns values to the resulting sequences, determining what is good. ProteoCraft allocates this verification budget through a coarse-to-fine paradigm: multi-site edits first explore distinct sequence basins, then verified promising states undergo strict single-site refinement. Across fourteen de novo binder-design settings spanning eight target proteins, five immune-relevant TCR-facing targets, and four localized CDR redesign tasks, ProteoCraft improves design quality and high-confidence yield. These improvements persist under independent AF2-IG and Rosetta-based interface evaluation. Prospective experimental validation further yielded an 82.9% binding hit rate for PD-L1 miniproteins, with a best measured KD of 0.879 nM, and confirmed binding of designed IFNAR2 VHH. Our code is available at https://github.com/smiles724/ProteoCraft_v1.

0.28

Learning Task-Specific Antibody Representations via Function-Aware Masking

cs.LG q-bio.BM ·2026-09-01 ·Ayan Goel, Thomas A. Walton, Amirali Aghazadeh
published similarity 0.62
Abstract · Accepted to MLCB 2026 (Oral)

Antibody-specific language models pretrained via masked language modeling (MLM) learn representations that are critical for downstream sequence design and property prediction tasks. Yet, the corruption process itself is rarely leveraged as a source of inductive bias during pretraining. While preferentially masking complementarity-determining regions (CDRs) improves binding-related predictions, antibodies possess diverse biological priors over a variety of functions. Herein, we introduce function-aware masking, a family of pretraining algorithms that align mask placement with specific functional priors (e.g., from IMGT annotations or structure predictions) to shape the learned representation space. We show that these specialist masking strategies significantly improve performance on their respective objectives, yielding up to a 14% gain on structure-related tasks and up to a 5.9x improvement on CDR-related tasks. To further improve performance across multiple functional axes, we develop hybrid masking strategies that integrate multiple priors, balancing reconstruction over binding, structural, and biophysical objectives. Our results demonstrate that informed mask placement provides a parameter-free mechanism for imposing functional inductive biases in antibody language model training.

0.31

Predictor-Guided Latent Space Codon Optimization for Maximizing Protein Expression

cs.AI cs.LG ·2026-10-02 ·Alberto Caron, Tianyu Cui, Dmytro S. Lituiev, Mangal Prakash, Artem Moskalev +11 more
similarity 0.62
Abstract

Codon optimization, the process of selecting synonymous codons to improve mRNA translation efficiency and protein expression, is central to therapeutic protein production and mRNA vaccines, yet it remains a hard problem. The design space is discrete and combinatorially large, precluding gradient-based methods, and existing tools rely on heuristic proxies (e.g., Codon Adaptation Index or GC-content) that poorly capture true expression. We introduce Latent-Space Codon Optimization (LSCO), which recasts this discrete problem as a continuous one by mapping sequences into the latent space of a pretrained mRNA language model, enabling efficient gradient-based search. LSCO combines four components: a data-driven expression objective from an uncertainty-aware predictor, a Minimum-Free-Energy regularizer for structural stability, a naturalness prior from a protein-to-codon back-translation model, and constrained decoding for protein fidelity. On a real-world, wet-lab antibody expression dataset, LSCO outperforms simple frequency-based, as well as modern deep generative baselines in predicted expression, while retaining suitable biophysical properties.

0.25

Can agents reliably design therapeutic antibodies?

cs.LG q-bio.QM ·2026-10-31 ·Asli Alpman, Nick Bhattacharya, Aaron Solomon, Hunter Elliott
similarity 0.61
Abstract

Recent work has demonstrated agents driving protein design workflows, either through orchestration of specialized tools or direct manipulation of sequences. Yet the fidelity with which agents follow protein design instructions and the factors contributing to their effectiveness remain understudied. We examine agentic antibody design under two settings: when explicit molecular-editing instructions are provided and when agents receive only previously-scored sequences and are prompted to propose improvements. We call the first task-guided and the second black-box design. For the task-guided setting, we curate ten expert-validated affinity-improvement tasks and show that LLM judges closely reproduce programmatic evaluations of instruction following. We then study two augmentations: access to antibody-relevant tools and to previously scored design history. Tools improve instruction following (IF) and sequence space exploration while reducing optimization performance, whereas design history reduces IF but improves optimization performance at the expense of exploration. Finally, we combine taskguided and black-box design within an in silico optimization loop and show that our agentic optimizer performs comparably to an established Bayesian optimization baseline.

0.08